Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

Galapagos licenses HUB Organoid Technology for use in cystic fibrosis and IBD research

Posted: 15 July 2015 | Victoria White

Galapagos has entered into a licensing agreement with the HUB foundation for use of Organoid Technology for preclinical research in cystic fibrosis and IBD…

Galapagos has entered into a licensing agreement with the Hubrecht Organoid Technology (HUB) foundation for use of Organoid Technology for preclinical research in cystic fibrosis and inflammatory bowel disease.

Organoids are mini-organs grown in cell culture from biopsies taken from patients; these mini-organs faithfully recapitulate the genetic and phenotypic characteristics of diseased tissues. Organoids have proven to be valuable disease models for the high-throughput screening and validation of innovative medicines, bypassing limitations associated with cell-line and xenograft-based preclinical drug studies.

Organoid Technology will potentially accelerate Galapagos’ discovery and development of drugs

Onno van de Stolpe, CEO of Galapagos, said, “The HUB’s Organoid Technology will add an exciting and cutting edge approach to Galapagos’ arsenal of research methods and potentially accelerate the discovery and development of our innovative drugs for cystic fibrosis and inflammatory bowel disease.”

 

Reserve your FREE place

 


Reduce preclinical failures with smarter off-target profiling

24 September 2025 | 15:00PM BST | FREE Webinar

Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.

What you’ll learn:

  • Approaches for prioritizing follow-up studies and refining risk mitigation strategies
  • How to interpret hit profiles from binding and functional assays
  • Strategies for identifying organ systems at risk based on target activity modulation
  • How to use visualization tools to assess safety margins and compare compound profiles

Register Now – It’s Free!

 

“We are pleased that the HUB and Galapagos have entered into this license agreement”, said Dr. Hans Clevers, board member of the HUB. “This partnership underpins the unique contribution of Organoid Technology to the development of drugs for patients with unmet medical needs, including patients with cystic fibrosis and inflammatory bowel disease.”

The HUB is a not-for-profit organization founded by the Hubrecht Institute, KNAW and University Medical Center Utrecht, The Netherlands. To find out more, please visit hub4organoids.eu.